Advertisement
Organisation › Details
Antag Therapeutics ApS
Antag Therapeutics is a biotech start-up developing peptide-based therapeutics for the treatment of dietary-related metabolic diseases. The company is a spinout from the University of Copenhagen and stems from the research groups of Professors Mette M. Rosenkilde and Jens J. Holst. *
Start | 2014-01-01 splitoff (date ca.) | |
Predecessor | University of Copenhagen | |
Industry | GIP antagonist | |
Industry 2 | drug development | |
Person | Sparre-Ulrich, Alexander Hovard (Antag Therapeutics 201706 CEO + Co-Founder) | |
Person 2 | Drejer, Kirsten (Symphogen 2000–201608 Founding CEO since 201609 Executive Director) | |
Region | København (Copenhagen) | |
Country | Denmark | |
Street | 3B Blegdamsvej | |
City | 2200 Copenhagen N | |
Tel | +45-21-456537 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Novo Holdings A/S. (6/26/17). "Press Release: Anti-obesity Start-up Antag Therapeutics ApS Raises 2.7 mEUR with Novo Seeds". Copenhagen. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Antag Therapeutics ApS
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top